AngioDynamics shares are finally showing signs of positive momentum. Click for this ANGO stock update and see if it is the ...

Q4 FY 2026. Management view "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year ...

Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. Revenue growth was led by med tech: AngioDynamics reported Q4 revenue up 8% to $86.6 million and full-year ...

AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid third-quarter fiscal 2026 performance, ...

ANGO's NanoKnife growth, strong Med Tech momentum and solid Q3 results support holding the stock despite tariff and inflation pressures.

Endologix, a medtech that focuses on treatments for vascular diseases, expanded its offerings with the purchase of a mechanical thrombectomy system from Surmodics. The deal for the Pounce thrombectomy ...

Endovascular thrombectomy is indicated for acute ischemic stroke due to a large vessel occlusion in the anterior circulation within 24 hours of the time last known to be well. The ORIENTAL-MeVO ...

Researchers at King's College London have shown for the first time that AI can autonomously perform thrombectomy navigation in a physical lab setting, a step toward expanding access to life-saving ...

Landmark, lifesaving telerobotic mechanical thrombectomy to expand access to care for stroke, a leading cause of death and disability worldwide HOUSTON & PANAMA CITY, Panama--(BUSINESS WIRE)--XCath, a ...

Two new randomized trials are reopening the question of whether thrombectomy may benefit selected patients with acute ischemic stroke caused by distal or medium vessel occlusions, a population in ...